Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis
- 1 January 2014
- journal article
- review article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 722, 26-37
- https://doi.org/10.1016/j.ejphar.2013.08.049
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2011
- The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In VivoThe Journal of pharmacology and experimental therapeutics, 2010
- Ablation of least shrew central neurokinin NK₁ receptors reduces GR73632-induced vomiting.Behavioral Neuroscience, 2009
- Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonistsBrain Research, 2008
- Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neuronsNeuroscience Letters, 2004
- Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonistsEuropean Journal of Cancer, 2003
- Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamidesJournal of Medicinal Chemistry, 1992
- Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced EmesisThe New England Journal of Medicine, 1990
- Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and VomitingThe New England Journal of Medicine, 1990
- MetoclopramideDrugs, 1983